RxDoctor Payments Data

Katie Geiser, NP

Nurse Practitioner · Grand Chute, WINPI 1013648591

Payments from drug & device makers

$1,853in general payments, 2019–2025

Across 69 payments — averaging $26.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$285
  • Boston Scientific$251
  • E.r. Squibb & Sons, L.L.C.$201
  • Pfizer$163
  • Alnylam Pharmaceuticals Inc.$159
  • Actelion Pharmaceuticals US, Inc.$128
  • plus $667 from 15 others

What the payments were for

  • Food & beverage$1,853100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,853 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$8,521
Medicare patients
118
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$207,640
XareltoRivaroxaban35$40,536
EntrestoSacubitril/Valsartan23$28,688
JardianceEmpagliflozin26$24,067
BrilintaTicagrelor13$13,952
Metoprolol Succinate125$1,971
Bumetanide29$1,452
Atorvastatin Calcium83$1,394
Furosemide146$930
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$806
Isosorbide Mononitrate ErIsosorbide Mononitrate49$662
Spironolactone58$653
Metoprolol Tartrate69$566
ClopidogrelClopidogrel Bisulfate37$494
Potassium Chloride27$492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$163$207,640190 claims
Johnson & JohnsonXarelto$52$40,53635 claims
NovartisEntresto$285$28,68823 claims
Boehringer IngelheimJardiance$56$24,06726 claims
AstraZenecaBrilinta$26$13,95213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Grand Chute

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →